Gate.io data on January 22nd, Ocean King Bio expects the vesting of net profit to shareholders of the listed company in 2024 to be a loss of 950 million to 1.2 billion yuan, a decrease of 1.69 billion yuan compared to the same period last year; after deducting non-recurring gains and losses, the net profit will be a loss of 1 billion to 1.25 billion yuan, a decrease of 1.74 billion yuan compared to the same period last year; the basic earnings per share will be a loss of 0.3611 yuan/share to 0.4561 yuan/share, a decrease of 0.6423 yuan/share compared to the same period last year. The expected operating income is 2.8 billion to 3.2 billion yuan, a decrease of 36.42 billion yuan compared to the same period last year. The main reasons are the decline in operating income, provision for impairment of goodwill of about 400 million to 570 million yuan, and provision for impairment of accounts receivable of about 230 million to 330 million yuan.
Ver originales
Esta página puede contener contenido de terceros, que se proporciona únicamente con fines informativos (sin garantías ni declaraciones) y no debe considerarse como un respaldo por parte de Gate a las opiniones expresadas ni como asesoramiento financiero o profesional. Consulte el Descargo de responsabilidad para obtener más detalles.
Haiwang Biology: se espera que la pérdida sea de 950 millones a 1.200 millones de yuanes en 2024
Gate.io data on January 22nd, Ocean King Bio expects the vesting of net profit to shareholders of the listed company in 2024 to be a loss of 950 million to 1.2 billion yuan, a decrease of 1.69 billion yuan compared to the same period last year; after deducting non-recurring gains and losses, the net profit will be a loss of 1 billion to 1.25 billion yuan, a decrease of 1.74 billion yuan compared to the same period last year; the basic earnings per share will be a loss of 0.3611 yuan/share to 0.4561 yuan/share, a decrease of 0.6423 yuan/share compared to the same period last year. The expected operating income is 2.8 billion to 3.2 billion yuan, a decrease of 36.42 billion yuan compared to the same period last year. The main reasons are the decline in operating income, provision for impairment of goodwill of about 400 million to 570 million yuan, and provision for impairment of accounts receivable of about 230 million to 330 million yuan.